YMI: YM Biosciences, Inc. (YMI on AMEX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : YMI: YM Biosciences, Inc. (YMI on AMEX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: John McCarthy	9/19/2009 12:36:27 AM
	of 66

Hmmmm ... What changed? Erbitux (ceuximab) Approved for Use in Combination with Radiation Therapy The most common adverse events reported for both treatment arms were mucositis and radiation dermatitis. The incidence of serious mucositis, radiation dermatitis and allergic/anaphylatoid reaction were > 2% higher in the RT + cetuximab arm when compared with RT alone. The following serious adverse reactions, some with fatal outcome were observed in the cetuximab plus RT arm: infusion reactions, cardiopulmonary arrest and/or sudden death and acneform rash. fda.gov

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next